MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Orthostatic hypotension(OH)"

  • MDS Virtual Congress 2021

    Locus coeruleus volume is reduced in Parkinson disease-related orthostatic hypotension.

    P. Beach, N. Kurra, K. Hwang, J. Langley, X. Hu, D. Huddleston (Atlanta, USA)

    Objective: To test whether structural pathology of the locus coeruleus (LC) is associated with orthostatic hypotension (OH) in Parkinson disease (PD). Background: OH is an…
  • MDS Virtual Congress 2021

    Leg muscle contractions compensate for declining cardiac baroreflex in PD Patients

    A. Huether, R. Fadil, R. Brunnemer, T. Harlow, A. Stutz, S. Matcha, A. Hanson, A. Blaber, K. Tavakolian, J-S. Lou (Fargo, USA)

    Objective: To investigate if impairments in muscle contraction affects blood pressure (BP) regulation in PD. Background: Orthostatic hypotension (OH) contributes to unexpected falls in PD.…
  • MDS Virtual Congress 2021

    A qualitative evaluation of the health-related quality of life impact on informal caregivers to patients with neurogenic orthostatic hypotension

    K. Gallop, N. Pham, G. Maclaine, E. Saunders, B. Black, S. Acaster (London, United Kingdom)

    Objective: This study aimed to explore the impact of caring for an individual with neurogenic orthostatic hypotension (nOH) through qualitative interviews with informal caregivers and…
  • MDS Virtual Congress 2020

    Orthostatic hypotension in early onset Parkinson’s disease

    Z. Liu, D.N Su, J.H Zhou, T. Feng (Beijing, China)

    Objective: To investigate Orthostatic hypotension (OH)  feature in early onset Parkinson's disease (EOPD)  , especially delayed OH and acute OH post drug.  To explore OH…
  • MDS Virtual Congress 2020

    The Clinical Heterogeneity of Orthostatic Hypotension in PD Patients

    P.Z Li, LL. Peng, J.L Wang, Y.M Liu (Jinan, China)

    Objective: The objects of the research were to investigate the clinical heterogeneity of orthostatic hypotension(OH) in PD Patients, to explore the possible risk factors for…
  • MDS Virtual Congress 2020

    Ampreloxetine (TD-9855), a long-acting, norepinephrine reuptake inhibitor (NRI) for the treatment of neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies: Phase 3 clinical program

    L. Norcliffe-Kaufmann, C. Shibao, I. Biaggioni, H. Kaufmann, W. Wang, R. Vickery, B. Haumann (New York, NY, USA)

    Objective: To confirm: 1) clinical efficacy and safety of once-daily oral ampreloxetine in a 4-week double-blind (DB), placebo-controlled (PC) study (NCT03750552); 2) durability of efficacy…
  • MDS Virtual Congress 2020

    Treatment of Neurogenic Orthostatic Hypotension (nOH) in Multiple System Atrophy (MSA) with a wearable Pneumatic Compression Garment utilising Soft Robotics

    N. Sawal, H. Singh, A. Beri (Chandigarh, India)

    Objective: To use a novel Pneumatic Garment device for treatment of nOH in MSA. Background: nOH is present in 66-90% of patients with MSA and…
  • MDS Virtual Congress 2020

    Both Symptomatic and Asymptomatic Orthostatic Hypotension is Associated with Cognitive Decline Over Time in Parkinson’s Disease

    K. Longardner, E. Bayram, I. Litvan (San Diego, CA, USA)

    Objective: To compare cognitive changes over time between Parkinson's disease (PD) patients with orthostatic hypotension (OH) and without OH, and between those with symptomatic OH…
  • MDS Virtual Congress 2020

    Orthostatic hypotension in Parkinson’s disease

    L. Dommershuijsen, A. Heshmatollah, P. Koudstaal, M. Ikram, M. Ikram (Rotterdam, Netherlands)

    Objective: We aimed to identify whether orthostatic hypotension (OH) is a prodromal marker of Parkinson’s disease (PD) or a symptom of later disease. Background: Many…
  • 2019 International Congress

    A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

    H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

    Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley